Back to search
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
Ischemic Stroke; Ischemic Attack, Transient
Clinicaltrials.gov:
EU CTIS:
#2022-501176-26-00
J&J ID:
#CR109231
Other:
#70033093STR3001
Subscribe or share this trial
Trials at a glance
Status
Enrollment complete
Condition
Ischemic Stroke; Ischemic Attack, Transient
Trial type
Interventional
Trial phase
Phase 3
Investigational
product
product
Milvexian
Placebo
Age
40+ years old
Biological sex
All
Placebo?
Yes
Trial start date
February 15, 2023
Trial end date
December 9, 2026
CT.gov ID
#NCT05702034
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Primary outcome measures
- Time to First Occurrence of Ischemic Stroke
Secondary outcome measures
- Time to First Occurrence of any Component of the Composite of Cardiovascular Death (CVD), Myocardial Infraction (MI), or Ischemic Stroke
- Time to First Occurrence of Ischemic Stroke
- Time to First Occurrence of any Component of Major Adverse Vascular Events (MAVE)
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
